Kiadis Pharma to present at upcoming conferences in June 2019
03 Junho 2019 - 12:45PM
Kiadis Pharma to
present at upcoming conferences in
June 2019
Amsterdam, The
Netherlands, June 3, 2019 - Kiadis Pharma N.V. ("Kiadis Pharma" or
the "Company") (Euronext Amsterdam and Brussels: KDS), a
clinical stage biopharmaceutical company, today announces it is
scheduled to attend the following conferences in June 2019.
Jefferies
2019 Global Healthcare Conference
June 4-7, 2019, New York, US
Management will
present on June 4th at 4:00pm
EDT and will host meetings with institutional investors.
European
Hematology Association Conference
June 13-16, 2019, RAI Amsterdam, Europaplein 24,
Amsterdam, The Netherlands
Dr Eduardo
Olavarria (Kiadis and Imperial College London, UK) will present an
abstract entitled "Phase 2 Study Evaluating
The Safety And Efficacy Of One Or Two Doses Of Donor Lymphocytes
Depleted Of Host Alloreactive T-cells (ATIR101) Following
T-cell-depleted Haploidentical HSCT" on June 14th at
5:30pm CEST.
Kiadis Contacts:
Kiadis Pharma:
Maryann Cimino, Manager, Corporate Affairs
Tel: +1 (617) 710-7305
m.cimino@kiadis.com
|
Optimum Strategic Communications:
Mary Clark, Supriya Mathur, Hollie Vile
Tel: +44 203 950 9144
David Brilleslijper (Amsterdam)
Tel: +31 610 942 514
kiadis@optimumcomms.com |
About Kiadis
Founded in 1997, Kiadis Pharma, is a fully integrated
biopharmaceutical company committed to developing innovative
therapies for patients with late-stage blood cancers. With
headquarters in Amsterdam, the Netherlands, and offices and
activities in the US and across Europe, Kiadis Pharma is
reimagining medicine by leveraging the natural strengths of
humanity and our collective immune system to source the best cells
for life.
Kiadis Pharma is listed on the
regulated market of Euronext Amsterdam and Euronext Brussels since
July 2, 2015, under the symbol KDS. Learn more at kiadis.com.
About ATIR101
ATIR101TM is an
investigational allodepleted T-cell immunotherapy product
candidate, which is designed to be given after a haploidentical
(genetically half-matched) hematopoietic stem cell transplantation
(HSCT).
Administered as an adjunctive
immunotherapeutic on top of HSCT, ATIR101 provides a single dose
donor lymphocyte infusion (DLI) with functional, mature immune
cells from a haploidentical family member. The T-cells in ATIR101
will help fight infections and remaining tumor cells, until the
immune system has fully re-grown from stem cells in the
transplanted graft.
In ATIR101, T-cells that would
cause GVHD are depleted from the donor lymphocytes, using our
photodepletion technology. At the same time, ATIR101 contains
potential cancer-killing T-cells from the donor that could
eliminate residual cancer cells and help prevent relapse of the
disease.
Forward Looking
Statements
Certain statements, beliefs and opinions in this
press release are forward-looking, which reflect Kiadis Pharma's
or, as appropriate, Kiadis Pharma's directors' current expectations
and projections about future events. By their nature,
forward-looking statements involve a number of risks, uncertainties
and assumptions that could cause actual results or events to differ
materially from those expressed or implied by the forward-looking
statements. These risks, uncertainties and assumptions could
adversely affect the outcome and financial effects of the plans and
events described herein. A multitude of factors including, but not
limited to, changes in demand, regulation, competition and
technology, can cause actual events, performance or results to
differ significantly from any anticipated development.
Forward-looking statements contained in this press release
regarding past trends or activities should not be taken as a
representation that such trends or activities will continue in the
future. As a result, Kiadis Pharma expressly disclaims any
obligation or undertaking to release any update or revisions to any
forward-looking statements in this press release as a result of any
change in expectations or any change in events, conditions,
assumptions or circumstances on which these forward-looking
statements are based. Neither Kiadis Pharma nor its advisers or
representatives nor any of its subsidiary undertakings or any such
person's officers or employees guarantees that the assumptions
underlying such forward-looking statements are free from errors nor
does either accept any responsibility for the future accuracy of
the forward-looking statements contained in this press release or
the actual occurrence of the forecasted developments. You should
not place undue reliance on forward-looking statements, which speak
only as of the date of this press release.
This
announcement is distributed by West Corporation on behalf of West
Corporation clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Kiadis Pharma N. V. via Globenewswire